My #1 Pre IPO Trade for 2025 – NAME and TICKER

One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...

Richard Scheller Biography and Net Worth

Director of Alector

Dr. Scheller has served as a member of our board of directors since October 2018. Dr. Scheller has been Chairman of Research and Development at BridgeBio, since January 2019. Previously, Dr. Scheller was Chief Scientific Officer at 23andMe, a personal genetics company from March 2015 to July 2019. From February 2001 to December 2014 Dr. Scheller was the Executive Vice President of Research and Early Development and a member of the Executive Committee at Genentech, Inc. From January 2009 to December 2014, Dr. Scheller was also a member of the Enlarged Executive Committee at Hoffmann-La Roche Ltd. Since February 2015, Dr. Scheller has served as a member of the board of directors for ORIC Pharmaceuticals, Inc. Since March 2015, Dr. Scheller has served as a member of the board of directors for Xenon Pharmaceuticals Inc. Since January 2018, Dr. Scheller has served as a member of the board of directors of BridgeBio Inc.

Dr. Scheller’s research on elucidating the molecular machinery and regulatory mechanism that underlie the release of neurotransmitters earned him the 2013 Albert Lasker Basic Medical Research Award. He is a member of the National Academy of Sciences and a member of the National Academy of Medicine. Dr. Scheller holds a Ph.D. in Chemistry from the California Institute of Technology and B.Sc. in Biochemistry from the University of Wisconsin-Madison. He completed his post-doctorate in Molecular Neurobiology at Columbia University.

What is Richard H. Scheller's net worth?: The estimated net worth of Richard H. Scheller is at least $30,758.55 as of May 5th, 2023. Dr. Scheller owns 8,427 shares of Alector stock worth more than $30,759 as of November 21st. This net worth evaluation does not reflect any other investments that Dr. Scheller may own. Learn More about Richard H. Scheller's net worth.
How do I contact Richard H. Scheller?: The corporate mailing address for Dr. Scheller and other Alector executives is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. Alector can also be reached via phone at (415) 231-5660 and via email at [email protected]. Learn More on Richard H. Scheller's contact information.
Has Richard H. Scheller been buying or selling shares of Alector?: Richard H. Scheller has not been actively trading shares of Alector over the course of the past ninety days. Most recently, Richard H. Scheller sold 56,260 shares of the business's stock in a transaction on Thursday, August 5th. The shares were sold at an average price of $27.68, for a transaction totalling $1,557,276.80. Learn More on Richard H. Scheller's trading history.
Who are Alector's active insiders?: Alector's insider roster includes Robert King (Insider), Robert Paul (Insider), Arnon Rosenthal (CEO), Richard Scheller (Director), Shehnaaz Suliman (COO), and Calvin Yu (VP). Learn More on Alector's active insiders.
Are insiders buying or selling shares of Alector?: During the last year, insiders at the sold shares 13 times. They sold a total of 162,311 shares worth more than $875,829.44. The most recent insider tranaction occured on September, 3rd when CFO Marc Grasso sold 7,297 shares worth more than $35,609.36. Insiders at Alector own 9.1% of the company. Learn More about insider trades at Alector.
Information on this page was last updated on 9/3/2024.

Richard H. Scheller Insider Trading History at Alector

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/5/2021	Sell	56,260	$27.68	$1,557,276.80
7/2/2021	Sell	9,981	$31.14	$310,808.34

Richard H. Scheller Buying and Selling Activity at Alector

Alector Company Overview

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Today's Range

Now: $3.65

$3.49

$3.67

50 Day Range

MA: $4.99

$3.64

$6.14

2 Week Range

Now: $3.65

$3.49

$8.90

Volume

332,799 shs

Average Volume

624,706 shs

Market Capitalization

$357.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66

My #1 Pre IPO Trade for 2025 – NAME and TICKER

From Wyatt Investment Research | Ad

The Next SpaceX Pre-IPO